Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19015637 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Gresko E, et al. (2009) PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage. Oncogene 28, 698-708 19015637
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S8-p - PML (human)
Orthologous residues
PML (human): S8‑p, PML iso2 (human): S8‑p, PML iso3 (human): S8‑p, PML iso4 (human): S8‑p, PML iso11 (human): S8‑p, PML iso14 (human): S8‑p, PML (mouse): S17‑p, PML iso2 (mouse): S17‑p, PML (rat): S8‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE HIPK2 (human)
Downstream Regulation
 Effect of modification (function):  sumoylation
 Effect of modification (process):  apoptosis, altered
 Comments:  induces sumoylation

S36-p - PML (human)
Orthologous residues
PML (human): S36‑p, PML iso2 (human): S36‑p, PML iso3 (human): S36‑p, PML iso4 (human): S36‑p, PML iso11 (human): S36‑p, PML iso14 (human): S36‑p, PML (mouse): S45‑p, PML iso2 (mouse): S45‑p, PML (rat): S36‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE HIPK2 (human)
Downstream Regulation
 Effect of modification (function):  sumoylation
 Effect of modification (process):  apoptosis, altered
 Comments:  induces sumoylation

S38-p - PML (human)
Orthologous residues
PML (human): S38‑p, PML iso2 (human): S38‑p, PML iso3 (human): S38‑p, PML iso4 (human): S38‑p, PML iso11 (human): S38‑p, PML iso14 (human): S38‑p, PML (mouse): S47‑p, PML iso2 (mouse): S47‑p, PML (rat): S38‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody
 Disease tissue studied:  bone cancer
 Relevant cell lines - cell types - tissues:  U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE HIPK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE HIPK2 (human) transfection of dominant-negative enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
adriamycin increase
U0126 inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  sumoylation
 Effect of modification (process):  apoptosis, altered
 Comments:  induces sumoylation


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.